¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"one gene/one enzyme"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • brancher enzyme
    °¡ÁöÄ¡±âÈ¿¼Ò, ºÐÁöÈ¿¼Ò
  • branching enzyme
    °¡ÁöÄ¡±âÈ¿¼Ò, ºÐÁöÈ¿¼Ò
  • constitutive enzyme
    ±âº»±¸¼ºÈ¿¼Ò
  • converting enzyme inhibitor
    Àüȯȿ¼Ò¾ïÁ¦Á¦
  • cytosolic enzyme
    ¼¼Æ÷¾×È¿¼Ò
  • debrancher enzyme
    °¡ÁöÁ¦°ÅÈ¿¼Ò, Å»ºÐÁöÈ¿¼Ò
  • digestive enzyme
    ¼ÒÈ­È¿¼Ò
  • double-sandwich enzyme-linked immunosorbent assay
    °ãÈ¿¼Ò¸é¿ªÃøÁ¤(¹ý)
  • extracellular enzyme
    ¼¼Æ÷¿ÜÈ¿¼Ò
  • enzyme
    È¿¼Ò
  • enzyme activity
    È¿¼ÒȰ¼º, È¿¼ÒȰ¼ºµµ
  • enzyme assay
    È¿¼ÒÃøÁ¤
  • enzyme immunoassay
    È¿¼Ò¸é¿ªºÐ¼®(¹ý)
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦
  • enzyme inhibitor
    È¿¼Ò¾ïÁ¦Á¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • structural gene
    ±¸Á¶À¯ÀüÀÚ
  • suicide gene
    ÀÚ»ìÀ¯ÀüÀÚ
  • supressor gene
    ¾ïÁ¦À¯ÀüÀÚ
  • tumor suppressor gene
    Á¾¾ç¾ïÁ¦À¯ÀüÀÚ
  • gene transfer
    À¯ÀüÀÚÀü´Þ
  • gene translocation
    À¯ÀüÀÚÀüÀ§
  • gene transfection
    1.À¯ÀüÀÚÀü´Þ°¨¿°, 2.À¯ÀüÀÚÇÙ³»ÁÖÀÔ
  • gene therapy
    À¯ÀüÀÚ¿ä¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gene amplification
    À¯ÀüÀÚÁõÆø
  • gene analysis
    À¯ÀüÀںм®
  • complementary gene
    º¸Á·À¯ÀüÀÚ, »óÈ£º¸ÃæÀ¯ÀüÀÚ
  • control gene
    Á¦¾îÀ¯ÀüÀÚ
  • cooperating gene
    Çùµ¿À¯ÀüÀÚ
  • gene cloning
    À¯ÀüÀÚŬ·Î´×
  • gene conversion
    À¯ÀüÀÚº¯È¯
  • determinant gene
    °áÁ¤À¯ÀüÀÚ
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ
  • duplicate gene
    º¹»çÀ¯ÀüÀÚ
  • gene defect
    À¯ÀüÀÚ°á¼Õ
  • gene deletion
    À¯ÀüÀÚ°á¼Õ
  • gene expression
    À¯ÀüÀÚ¹ßÇö
  • gene frequency
    À¯ÀüÀÚºóµµ
  • gene
    À¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glycolytic enzyme
    ÇØ´çÈ¿¼Ò
  • heterogeneous enzyme immunoassay
    ºÒ±ÕÀÏ<--Áú>È¿¼Ò¸é¿ªÇÐÀûÃøÁ¤(¹ý)
  • homogeneous enzyme immunoassay
    ±ÕÁúÈ¿¼Ò¸é¿ªÃøÁ¤(¹ý)
  • induced enzyme
    À¯µµÈ¿¼Ò.
  • inducible enzyme
    À¯µµ(¹ß)È¿¼Ò.
  • inducible enzyme
    À¯¹ß°¡´ÉÈ¿¼Ò
  • inhibitory enzyme
    ÀúÇØÈ¿¼Ò.
  • inorganic enzyme
    ¹«±âÈ¿¼Ò(ÙíѦý£áÈ).
  • phosphorylating enzyme
    ÀλêÈ­È¿¼Ò(ìÝß« ûùý£áÈ).
  • prosthetic group-labeled enzyme
    º¸Á¶±ºÇ¥ÁöÈ¿¼Ò
  • rate limiting enzyme
    ¼ÓµµÁ¶ÀýÈ¿¼Ò(áÜöôðàï½ý£áÈ).
  • receptor destroying enzyme
    ¼ö¿ëüÆÄ±«È¿¼Ò(¡­÷òÎÕý£áÈ).
  • redox enzyme
    »êȭȯ¿øÈ¿¼Ò(ß«ûùü»êªý£áÈ).
  • reducing enzyme
    ȯ¿øÈ¿¼Ò(ü½êªý£áÈ).
  • regulatory enzyme
    Á¶ÀýÈ¿¼Ò(¡­ý£áÈ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • one sided dominance
    ÀÏÃø¿ì¼º(ìéö°éÐàõ).
  • one stage sampling
    ÀÏ´Ü(Ç¥º»)ÃßÃâ¹ý(ËöËÀ̰ËÓ̧̧ËÑ).
  • one step growth
    ÀÏ´ÜÁõ½Ä(ìéÓ«ñòãÖ).
  • one step growth curve
    ÀÏ´ÜÁõ½Ä°î¼±(¡­ÍØàÊ).
  • one step growth experiment
    ÀÏ´ÜÁõ½Ä½ÇÇè(¡­ãùúÐ).
  • one step high level resistance
    ÀÏ´Ü°è °íµµ ³»¼ºÈ¹µæ, ÀÏȸ °í³»¼ºÈ¹µæ
  • one way layout
    ÀÏ¿ø¹èÄ¡¹ý(ìéêªÛÕöÇÛö).
  • one way valve
    ÀϹæÆÇ(ìéÛ°÷û).
  • one-piece lens
    ÀÏü·»Áî
  • one-probe method
    ´ÜÀÏ (Ó¤ìé) Æ®·£½ºµà¼­ ¹æ½Ä (Û°ãÒ)
  • resistance, one-way cross
    ±³Â÷ÀϹ泻¼º
  • test, one leg raising
    ´Ü°¢±â¸³°Ë»ç
  • adaptive enzyme
    ÀûÀÀÈ¿¼Ò(îêëëý£áÈ).
  • allosteric enzyme
    ¾Ë·Î½ºÅ׸®È¿¼Ò(¡­ý£áÈ).
  • angiotensin converting enzyme
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • diversity gene
    ´Ù¾ç¼º À¯ÀüÀÚ(ÒýåÆàõë¶îîí­) = D gene
  • dominant gene
    ¿ì¼º À¯ÀüÀÚ(éÐàõë¶îîí­)
  • duplicate gene
    º¹»ç À¯ÀüÀÚ(ÜÜÞÐë¶îîí­)
  • early gene
    Á¶±â À¯ÀüÀÚ (ðÄÑ¢ë¶îîí­)
  • epistatic gene
    ¿ìÀ§ À¯ÀüÀÚ (éÐêÈë¶îîí­)
  • essential gene
    Çʼö À¯ÀüÀÚ (ù±âÎë¶îîí­)
  • fused gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
  • fusion gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
  • gene
    À¯ÀüÀÚ(ë¶îîí­)
  • gene activation
    À¯ÀüÀÚ È°¼ºÈ­(ë¶îîí­üÀàõûù)
  • gene amplification
    À¯ÀüÀÚ ÁõÆø(ë¶îîí­ñòøë)
  • gene bank
    À¯ÀüÀÚ ÀºÇà(ë¶îîí­ëÞú¼)
  • gene cloning
    À¯ÀüÀÚ(ë¶îîí­) Ŭ·Î´×
  • gene cluster
    À¯ÀüÀÚ(ë¶îîí­) ¼ÛÀÌ
  • gene conversion
    À¯ÀüÀÚ Àüȯ(ë¶îîí­ï®üµ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CGRPs Calcitonin Gene-Related Products
GnRH Gonadotropin Releasing Hormone  [HP 1898, 2034]
  = LHRH
  = Go...
ss semis; one half; ¹Ý
ARGS antitrypsin-related gene sequence
beta [Greek letter beta] an anomer of a carbohydrate; buffer capacity; carbon separated from a carboxyl by one other carbon i...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
20 alpha-OH-P 20 alpha-hydroxy-4-pregnan-3-one
CR1 Complement receptor type one
FEV1 Forced Expiratory Volume at one second
FEV-1 forced expiratory volumes in one second
FEV1.0 Forced Expiratory Volume in one second
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • exaggeration gene
    °­Á¶ À¯ÀüÀÚ
  • fcc gene
    FCC À¯ÀüÀÚ
  • histocompatibility gene
    Á¶Á÷ ÀûÇÕ À¯ÀüÀÚ, Á¶Á÷ ÀûÇÕ¼º À¯ÀüÀÚ
    ÀÌ½ÄµÈ Á¶Á÷À» ÀÚ±â Á¶Á÷ ¶Ç´Â ¿ÜºÎ Á¶Á÷À¸·Î ÀνÄÇÏ´Â À¯ÀüÀÚ.
  • Is gene
    Is À¯ÀüÀÚ
  • marker gene
    Ç¥Áö À¯ÀüÀÚ
  • multiple drug resistance gene
    º¹ÇÕ ¾àÁ¦ ³»¼º À¯ÀüÀÚ
  • mutable gene
    À̺¯ À¯ÀüÀÚ
  • mutator gene
    º¯ÀÌ À¯¹ß À¯ÀüÀÚ
  • nucleolar gene
    ÇÙ ¼Òü À¯ÀüÀÚ
  • operator gene
    ÀÛµ¿ À¯ÀüÀÚ
  • recessive gene
    ¿­¼º À¯ÀüÀÚ
    ¿­¼º ÈÄÅð ¶Ç´Â ÇÔ¿äÇϱ⠽¬¿î °Í. Áö¹è·ÂÀ» ³ªÅ¸³»Áö ¸øÇϰųª ¿µÇâ·ÂÀ» ÅëÁ¦ÇÏÁö ¸øÇÏ´Â °Í. À¯ÀüÇп¡¼­´Â ´ë¸³ À¯ÀüÀÚ°¡ »óµ¿ ¿°»öü »ó¿¡ ¾øÀ¸¸é ÇüÁúÀ» ¹ßÇöÇÏÁö ¸øÇÏ´Â °Í.
  • regulator gene
    Á¶Àý À¯ÀüÀÚ
  • regulatory gene
    Á¶Àý À¯ÀüÀÚ
  • structural gene
    ±¸Á¶ À¯ÀüÀÚ
  • virulence gene
    µ¶¼º À¯ÀüÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
acetyl-activating enzyme A ligase that catalyses the reaction of acetate and CoA and ATP to form AMP, pyrophosphate, and acetyl-CoA. A key step in the activation of acetate.
Synonym: acetate thiokinase, acetate-CoA ligase, acetyl-activating enzyme, acetyl-CoA synthetase.
(05 Mar 2000)
acyl-activating enzyme <enzyme> Fatty acid thiokinase (long-chain), a ligase forming acyl-CoA, AMP, and pyrophosphate from long-chain fatty acids, ATP, and coenzyme A. Activity is independent of phosphatidylcholine
Registry number: EC 6.2.1.3
Synonym: acyl-activating enzyme, dodecanoyl-CoA synthetase, fatty acid thiokinase (long chain), acid-coenzyme a ligase, fatty acid-CoA ligase, acyl-CoA synthetase, acyl-CoA ligase, coash ligase, ciprofibroyl-CoA synthetase, pristanoyl-CoA synthetase, palmityl CoA synthetase, palmitoyl CoA synthetase, palmitoyl CoA ligase, fatty acyl-CoA synthetase, very long chain fatty acid acyl-CoA synthetase, vlcfa acyl-CoA synthetase, nafenopin-CoA ligase, palmitoyl-CoA synthase, faa2 gene product, faa2p protein, vlacs enzyme
(26 Jun 1999)
adaptive enzyme Inducible enzyme, an enzyme that can be detected in a growing culture of a microorganism, after the addition of a particular substance (inducer) to the culture medium, but was not detectable prior to the addition and can act on the inducer. A prototype is the beta-galactosidase of Escherichia coli, synthesised upon the addition of various galactosides, whether or not these are good substrates.
Compare: constitutive enzyme.
Synonym: adaptive enzyme.
(05 Mar 2000)
allosteric enzyme <biochemistry, chemistry> A regulatory enzyme whose activity is modified by the noncovalent binding of a particular metabolite at a site (the allosteric site) other than the active site.
(09 Oct 1997)
amino acid activating enzyme <enzyme> Enzymes catalyzing the formation of a specific aminoacyl-tRNA from an amino acid and adenosine 5'-triphosphate with the concomitant formation of adenosine 5'-monophosphate and pyrophosphate.
Synonym: amino acid activating enzyme, aminoacyl-tRNA ligases.
(05 Mar 2000)
angiotensin-converting enzyme <enzyme> This hydrolase enzyme cleaves the decapeptide angiotensin I (biologically inactive) to form active angiotensin II by angiotensin-converting enzyme which removes a dipeptide (histidylleucine) from angiotensin I.
Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases.
Elevations in angiotensin converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels).
Drugs that inhibit ACE are used to treat hypertension and congestive heart failure.
See: angiotensin-converting enzyme inhibitor
Acronym: ACE
(12 Aug 2000)
angiotensin-converting enzyme inhibitor <pharmacology> A class of drugs used in the treatment of hypertension and heart failure.
They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
(14 Aug 2000)
angiotensin-converting enzyme secretase <enzyme> Converts ace from a membrane-bound to a soluble form; not inhibited by thiol, serine or acid enzyme inhibitor but is inhibited by edta and 1,10-phenanthroline
Registry number: EC 3.4.99.-
Synonym: ace secretase
(26 Jun 1999)
Antibody Directed Enzyme Prodrug Therapy <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately.
The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects.
Acronym: ADEPT
(14 Nov 1997)
antitumour enzyme <enzyme> An enzyme that stimulates the degradation of a particular metabolite that cannot be synthesised by tumour cells, inhibits the synthesis of a metabolite needed by tumour cells, or inhibits tumour-specific DNA utilization; e.g., asparaginase.
(05 Mar 2000)
autolytic enzyme <enzyme> An enzyme capable of causing lysis of the cell forming it.
(05 Mar 2000)
beta-carotene cleavage enzyme <enzyme> An enzyme catalyzing the reaction of beta-carotene plus O2 producing two retinals.
Synonym: beta-carotene cleavage enzyme, carotenase, carotinase.
(05 Mar 2000)
branching enzyme 1,4-alpha-d-glucan branching enzyme
cardiac enzyme <biochemistry> A group of enzymes found normally in heart tissue. Cardiac enzymes are released into the blood stream in increased concentration when the heart muscle becomes damaged.
Examples include SGOT, CPK-MB and LDH.
(27 Sep 1997)
pancreatic enzyme <biochemistry> One of the proteins made by the pancreas that aid digestion of fats, carbohydrates and proteins.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gene manipulation
    À¯ÀüÀÚ Á¶ÀÛ(ÀÎÀ§ÀûÀ¸·Î À¯ÀüÀÚ¸¦ ¿Å±â°Å³ª ¿°»öü µîÀ» º¯È­½Ã۱â)
  • gene mapping
    À¯ÀüÀÚ Áöµµ(¿°»öü»óÀÇ À¯ÀüÀÚ ÀÚ¸®¸¦ °áÁ¤Çϱâ)
  • gene pool
    À¯ÀüÀÚ Ç®;À¯ÀüÀÚ °ø±Þ¿ø(¸àµ¨ Áý´ÜÀ» ±¸¼ºÇÏ´Â ¸ðµç °³Ã¼°¡ °¡Áö°í ÀÖ´Â À¯ÀüÀÚ Àüü)
  • gene therapy
    À¯ÀüÀÚ ¿ä¹ý(°á¼ÕµÈ À¯ÀüÀÚ¸¦ º¸ÃæÇÏ¿© À¯Àüº´À» °íÄ¡´Â ¿ä¹ý)
  • nif gene
    (»ýÈ­)Áú¼Ò °íÁ¤¿¡ °ü¿©ÇÏ´Â À¯ÀüÀÚ
  • recessive gene
    ¿­¼º À¯ÀüÀÚ
  • regulator(regulatory) gene
    Á¶Àý(Á¦¾î)À¯ÀüÀÚ
  • restorer gene
    ȸº¹ À¯ÀüÀÚ
  • a word in one's ear
    ±Ó¼Ó¸»
  • acquaint one with
    ´©±¸¿¡°Ô - ¾Ë¸®´Ù; ¼Ò°³ÇÏ´Ù
  • at one's command
    ..À» ¸¶À½´ë·Î ÇÒ¼ö ÀÖ´Â
  • bide one's time
    ÁÁÀº½Ã±â¸¦ ±â´Ù¸®´Ù
  • do one's best
    ÃÖ¼±À» ´ÙÇÏ´Ù
  • drag one's feet
    ²Ù¹°°Å¸®´Ù
  • for one thing
    ù°·Î,ÇѰ¡Áö
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á